Organisation paid for research Program year 2025 Source: CMS Open Payments

Eastern Nephrology Associates PLLC

Neither a doctor nor a teaching hospital

Research payments

$857,410

1,219 payments

Through program year 2025, Eastern Nephrology Associates PLLC is reported as receiving $857,410 in research payments, across 1,219 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$79,438	5
2024	Research	$8,134	3
2023	Research	$5,000	1
2022	Research	$41,553	619
2021	Research	$155,896	169
2020	Research	$313,572	116
2019	Research	$253,817	306

Breakdown

Who paid Research payments · program years 2019–2025

Akebia Therapeutics Inc $719,892 1,198 payments
Eli Lilly and Company $79,438 5 payments
Sanofi US Services Inc. $43,819 11 payments
Aurinia Pharma U.S., Inc. $13,134 4 payments
Lexicon Pharmaceuticals, Inc. $1,127 1 payment

Studies the money was for Research payments · program years 2019–2025

Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Conversion) $157,592 57 payments
Akb-6548-Ci-0015 $127,488 399 payments
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) $125,646 51 payments
Akb-6548-Ci-0014 $124,062 515 payments
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease $79,438 5 payments
Akb-6548-Ci-0014 $78,879 86 payments
Akb-6548-Ci-0015 $77,017 83 payments
A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Sever $43,819 11 payments
Study of Krx-0502 (Ferric Citrate) Dose Regimens in Subjects With Non-Dialysis Dependent Chronic Kidney Disease and Iron-Deficiency Anemia $29,207 7 payments
LUPKYNIS Registry Study $13,134 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.